NEOVACS (ALNEV.PA)

Company Profile

Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Company Info

NEOVACS

3-5, Impasse Reille

Paris ILE-DE-FRANCE

P: 33153109300

Employees: 22

Website: https://www.neovacs.com/fr/